GNLX: Genelux Corp insider trading, 5% holders and institutional ownership
From public SEC filings: open-market insider purchases and sales (Form 4, last 180 days), holders of 5% or more (Schedules 13D and 13G) and institutional ownership (Form 13F). Insider and 5% data delayed 48 hours.
Insider trading
0 open-market buys totaling - and 0 sales totaling - in the last 180 days.
Institutional ownership (Q2 2026)
72 institutions reported holding $29.37M of Genelux Corp on Form 13F (71 the quarter before). 10 opened a new position and 10 sold out. Shares held by institutions: +5%.
| Largest holders | Shares | Value |
|---|---|---|
| WOODWARD DIVERSIFIED CAPITAL, LLC | 2,262,108 | $6.81M |
| VANGUARD CAPITAL MANAGEMENT LLC | 1,677,724 | $5.05M |
| Bleichroeder LP | 1,380,666 | $4.16M |
| BlackRock, Inc. | 439,602 | $1.32M |
| GEODE CAPITAL MANAGEMENT, LLC | 439,213 | $1.32M |
| CM Management, LLC | 400,000 | $1.20M |
| BANK OF AMERICA CORP /DE/ | 328,803 | $990K |
| VANGUARD FIDUCIARY TRUST CO | 236,344 | $711K |
| FLPUTNAM INVESTMENT MANAGEMENT CO | 231,405 | $697K |
| Global Retirement Partners, LLC | 227,854 | $686K |
Clinical trial readouts
2 Phase 2 or 3 trials by Genelux Corp with a primary completion date in the last 90 days or the next 12 months and no results posted yet, from ClinicalTrials.gov. (est.) = company estimate.
| Primary completion | Drug | Condition | Phase | Patients | Status | Trial |
|---|---|---|---|---|---|---|
| 2026-12 (est.) | olvimulogene nanivacirepvec | Platinum-resistant Ovarian Cancer | Phase 3 | 186 | Recruiting | NCT05281471 |
| 2027-02 (est.) | Olvimulogene nanivacirepvec | Advanced Non-squamous Non-small-cell Lung Cancer | Phase 2 | 142 | Recruiting | NCT06463665 |
Get new insider and activist filings the morning after: daily alerts. Not investment advice.